Biblio

38 resultats trouvés
Filtres: Auteur is Gyan, Emmanuel  [Clear All Filters]
A
Labreche K, Daniau M, Sud A, Law PJ, Royer-Perron L, Holroyd A, Broderick P, Went M, Benazra M, Ahle G et al..  2019.  A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study. NEURO-ONCOLOGY. 21:1039-1048.
Jaimes-Albornoz D, Mannone L, Nguyen-Quoc S, Chalandon Y, Chevallier P, Mohty M, Meunier M, Robin M, Ledoux M-P, Guillerm G et al..  2019.  Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 25:2366-2374.
Touzeau C, Leux C, Bouabdallah R, Roussel M, Delarue R, Bouabdallah K, Thieblemont C, Cacheux V, Cartron G, Compain L et al..  2014.  Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. ANNALS OF HEMATOLOGY. 93:233-242.
B
Cornillon J, Daguenet E, Bay J-O, Chauchet A, Salles G, Contentin N, Nicolas-Virelizier E, Mercier M, Vallet N, Alexis M et al..  2019.  BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). ANNALS OF HEMATOLOGY. 98:1973-1980.
Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F, Malak S, Sibon D, Broussais F, Braun T et al..  2016.  Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. ONCOTARGET. 7:85573-85583.
Reboursiere E, Le Bras F, Morschhauser F, Gyan E, Clavert A, Malak S, Sibon D, Damge M, Gardin C, Fornecker L-M et al..  2015.  Bendamustine Treatment in Refractory or Relapsed T Cell Lymphomas: A Retrospective Multicenter Study. BLOOD. 126
Chantepie S, Tchernonog E, Peyrade F, Larcher M-V, Diouf M, Fornecker LMathieu, Houot R, Gastinne T, Soussain C, Malak S et al..  2016.  Bendamustine-Based (BeEAM) Conditioning before Autologous Stem Cell Transplantation: Result of a French Multicenter Study of 386 Patients from Lysa Centers. BLOOD. 128
C
Paillassa J, Di Blasi R, Chevret S, Bernard S, Darmon M, Meignin V, Deau-Fischer B, Camus V, Casasnovas R-O, Cartron G et al..  2019.  CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria. BLOOD. 134
Laboure G, Parrens M-C, Tsaranazy A, Bordier M, Le Gouill S, Delwail V, Gressin R, Cornillon J, Damaj G, Foussard CYves et al..  2015.  Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) :. BLOOD. 126
Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H et al..  2017.  Consolidation anti-CD22 fractionated radioimmunotherapy with Y-90-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. LANCET HAEMATOLOGY. 4:E35-E45.
Bris YLE, Canioni D, Burroni B, Moreau A, Tessoulin B, Magrangeas F, Delfau M-H, Thieblemont C, Oberic L, Bouabdallah K et al..  2018.  Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group. BLOOD. 132
D
Gac A-C, Azar N, Daguindau E, Cartron G, Fornecker LM, Gyan E, Broussais-Guillaumot F, Garidi R, Choufi B, Chantepie SP et al..  2016.  Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases LEUKEMIA & LYMPHOMA. 57:1149-1153.
I
Cahu X, Carre M, Recher C, Pigneux A, Hunault-Berger M, Vey N, Chevallier P, Delaunay J, Gyan E, Lioure B et al..  2017.  Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia. EUROPEAN JOURNAL OF HAEMATOLOGY. 98:443-449.
Lam M, Touitou V, Choquet S, Cassoux N, Ghesquieres H, Kodjikian L, Schmitt A, Gattoussi S, Tabouret E, Sampo M et al..  2021.  Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study. AMERICAN JOURNAL OF HEMATOLOGY. 96:823-833.
M
Houillier C, Soussain C, Ghesquieres H, Soubeyran P, Chinot O, Taillandier L, Lamy T, Choquet S, Ahle G, Damaj G et al..  2020.  Management and outcome of primary CNS lymphoma in the modern era An LOC network study. NEUROLOGY. 94:E1027-E1039.
Lazarovici J, Brice P, Oberic L, Gaillard I, Hunault-Berger M, Broussais F, Bologna S, Gyan E, Sebban C, Touati M et al..  2014.  Management and Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Retrospective Study By the Lymphoma Study Association. BLOOD. 124
Boussen I, Algrin C, Rossignol J, Durot E, Guenounou S, Bonnet A, Delage J, Gyan E, Bijou F, Milpied N et al..  2016.  Management of Post-Transplant Lymphoproliferative Disorders in the Real Life: The French Attitude Between 2010 and 2013. BLOOD. 128
N
Lazarovici J, Dartigues P, Brice P, Oberic L, Gaillard I, Hunault-Berger M, Broussais-Guillaumot F, Gyan E, Bologna S, Nicolas-Virelizier E et al..  2015.  Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study. HAEMATOLOGICA. 100:1579-1586.
O
Tessoulin B, Chiron D, Thieblemont C, Oberic L, Bouadballah K, Gyan E, Damaj G, Ribrag V, Gressin R, Feugier P et al..  2021.  Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. BONE MARROW TRANSPLANTATION. 56:1700-1709.
P
Bris YLE, Theisen O, Moreau A, Magrangeas F, Canioni D, Burroni B, Thieblemont C, Oberic L, Bouabdallah K, Gyan E et al..  2018.  Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy - a Study By the Lysa Group. BLOOD. 132
Callanan MB, Delfau M-H, Macintyre E, Thieblemont C, Oberic L, Gyan E, Bouabdallah K, Gressin R, Damaj G, Casasnovas O et al..  2015.  Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Interim Results from the LyMa-MRD Project,. BLOOD. 126
Callanan MB, Delfau M-H, Macintyre E, Thieblemont C, Oberic L, Gyan E, Bouabdallah K, Gressin R, Damaj G, Casasnovas O et al..  2015.  Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Interim Results from the LyMa-MRD Project,. BLOOD. 126
Bodet-Milin C, Bailly C, Meignan M, Beriollo-Riedinger A, Casasnovas R-O, Devillers A, Lamy T, Santiago-Ribeiro M, Gyan E, Gallazzini-Crepin C et al..  2015.  Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group. BLOOD. 126
Langner-Lemercier S, Houillier C, Soussain C, Ghesquieres H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A et al..  2016.  Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. NEURO-ONCOLOGY. 18:1297-1303.
Bailly C, Carlier T, Berriolo-Riedinger A, Casasnovas O, Gyan E, Meignan M, Moreau A, Burroni B, Djaileb L, Gressin R et al..  2020.  Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. HAEMATOLOGICA. 105:E33-E36.

Pages